Alaunos Therapeutics, Inc. TCRT
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-08-20 |
| Shares Out. | 3,610,000 |
| Website | alaunos.com/ ↗ |
| Phone | 13026365400 |
| Employees | 1 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$952,000 |
| Free Cash Flow | -$2.8M |
| Total Assets | $1.5M |
| Total Liabilities | $864,000 |
| Equity | $652,000 |
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Alaunos Therapeutics, Inc. is a publicly traded company under the ticker symbol TCRT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2025-03-01)